The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study

被引:85
|
作者
Yang, WH
Drouin, MA
Herbert, M
Mao, Y
Karsh, J
机构
[1] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[2] HLTH CANADA, LAB CTR DIS CONTROL, OTTAWA, ON K1A 0L2, CANADA
[3] HLTH CANADA, BUR CHRON DIS EPIDEMIOL, OTTAWA, ON K1A 0L2, CANADA
关键词
monosodium glutamate; monosodium glutamate symptom complex; randomized double-blind challenge;
D O I
10.1016/S0091-6749(97)80008-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Considerable debate swirls about the validity of symptoms described by many people after ingestion of monosodium glutamate (MSG), and the question has remained unresolved largely because of a paucity of well-designed challenge studies. Methods: We conducted oral challenge studies in self-identified MSG-sensitive subjects to determine whether they had a statistically significant difference in the incidence of their specific symptoms after ingestion of MSG compared with placebo. First, 5 gm MSG or placebo was administered in random sequence in a double-blind fashion. Subjects who reacted only to a single test agent then underwent rechallenge in random sequence in a double-blind fashion with placebo and 1.25, 2.5, and 5 gm MSG. A positive response to challenge was defined as the reproduction of greater than or equal to 2 of the specific symptoms in a subject ascertained on prechallenge interview. Results: Sixty-one subjects entered the study. On initial challenge, 18 (29.5%) responded to neither MSG nor placebo, 6 (9.8%) to both, 15 (24.6%) to placebo, and 22 (36.1%) to MSG (p = 0.324). Total and average severity of symptoms after ingestion of MSG (374 and 80) were greater than respective values after placebo ingestion (232 and 56; p = 0.026 and 0.018, respectively). Rechallenge revealed an apparent threshold dose for reactivity of 2.5 gm MSG. Headache (p < 0.023), muscle tightness (p < 0.004), numbness/tingling (p < 0.007), general weakness (p < 0.040), and Bushing (p < 0.016) occurred more frequently after MSG than placebo ingestion. Conclusions: Oral challenge with MSG reproduced symptoms in alleged sensitive persons. The mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism. According to Food and Drug Administration recommendations, the symptoms, originally called the Chinese restaurant syndrome, are better referred to as the MSG symptom complex.
引用
收藏
页码:757 / 762
页数:6
相关论文
共 50 条
  • [1] Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study
    Geha, RS
    Beiser, A
    Ren, C
    Patterson, R
    Greenberger, PA
    Grammer, LC
    Ditto, AM
    Harris, KE
    Shaughnessy, MA
    Yarnold, PR
    Corren, J
    Saxon, A
    JOURNAL OF NUTRITION, 2000, 130 (04): : 1058S - 1062S
  • [2] The administration to Indonesians of monosodium L-glutamate in Indonesian foods: An assessment of adverse reactions in a randomized double-blind, crossover, placebo-controlled study
    Prawirohardjono, W
    Dwiprahasto, I
    Astuti, I
    Hadiwandowo, S
    Kristin, E
    Muhammad, M
    Kelly, MF
    JOURNAL OF NUTRITION, 2000, 130 (04): : 1074S - 1076S
  • [3] DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY (DBPCRS) TO EVALUATE REACTIONS ALLEGEDLY DUE TO THE CONSUMPTION OF MONOSODIUM GLUTAMATE (MSG) - THE CANADIAN STUDY
    YANG, WH
    DROUIN, MA
    HERBERT, M
    MAO, Y
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 304 - 304
  • [4] PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND STUDY OF INCOBOTULINUMTOXINA FOR SIALORRHEA
    Jost, W.
    Friedman, A.
    Michel, O.
    Oehlwein, C.
    Slawek, J.
    Bogucki, A.
    Ochudlo, S.
    Banach, M.
    Pagan, F.
    Flatau-Baque, B.
    Csikos, J.
    Cairney, C. J.
    Blitzer, A.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 40 - 40
  • [5] CETACAINE EFFICACY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    LACHTER, J
    JACOBS, R
    LAVY, A
    SUISSA, A
    WEISLER, A
    EIDELMAN, S
    GASTROENTEROLOGY, 1988, 94 (05) : A245 - A245
  • [6] DOUBLE-BLIND PLACEBO-CONTROLLED CHALLENGE (DBPCC) OF PERSONS REPORTING ADVERSE REACTIONS TO MONOSODIUM GLUTAMATE (MSG)
    ALTMAN, DR
    FITZGERALD, T
    CHIARAMONTE, LT
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (01) : 303 - 303
  • [7] Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate
    Geha, RS
    Beiser, A
    Ren, C
    Patterson, R
    Greenberger, PA
    Grammer, LC
    Ditto, AM
    Harris, KE
    Shaughnessy, MA
    Yarnold, PR
    Corren, J
    Saxon, A
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (05) : 973 - 980
  • [8] Dexamethasone for Symptom Distress in Advanced Cancer: A Double-Blind, Randomized, Placebo-Controlled Trial
    Yennurajalingam, Sriram
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (02) : 337 - 337
  • [9] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [10] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Taslimi, Shervin
    Vahidi, Hamed
    Pourvaziri, Ali
    Modabbernia, Amirhossein
    Fallah, Arezoo Yeke
    Yazdani, Nasrin
    Taslimi, Negin
    Hosseini, Mostafa
    Zarandi, Masoud Motesadi
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (05) : 1635 - 1641